Market Overview:
The recombinant protein vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of this market is mainly attributed to the increasing prevalence of infectious diseases, growing demand for animal-derived vaccines, and rising investments in R&D for novel vaccine technologies. The recombinant protein vaccine market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into bacterial cells culture vaccines and mammalian cells culture vaccines. Bacterial cells culture vaccines are further sub-segmented into Streptococcus pneumoniae (pneumococcal), Haemophilus influenzae type b (Hib), Neisseria meningitidis (meningococcal), and others; while mammalian cells culture vaccines are further sub-segmented into human papillomavirus (HPV), hepatitis B virus (HBV), rabies virus, varicella zoster virus (VZV) and others. On the basis of application, the recombinant protein vaccine market is segmented into human applications and animal applications. Human applications are further sub-segmented into prophylactic vaccinations and therapeutic vaccinations; while animal applications are further sub-segmented into veterinary prophylactic vaccinations and veterinary therapeutic vaccinations. Geographically, the recombinant protein vaccine market is segmented into North America, Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
A recombinant protein vaccine is a vaccine that contains a recombinant antigen. Recombinant vaccines are made by transferring genetic material from one organism to another. The transferred genetic material can be from the same or different species.
Bacterial Cells Culture:
Bacterial cells culture is a process to grow bacteria or bacterial cells under controlled conditions. The most commonly used bacteria are Escherichia coli, Bacillus subtilis, and Salmonella typhimurium. These three species of bacteria are generally used in recombinant protein vaccine production as they can grow at high temperatures (TBP), have large fermentation capacity (LTB), and possess the ability to grow in the presence of minimal nutrients (ATP).
Mammalian Cells Culture:
Mammalian cells culture and it's usage in recombinant protein vaccine market is expected to witness significant growth over the forecast period. The primary factors that propel the growth of this industry include growing incidences of infectious diseases, increasing demand for animal-based proteins, rising awareness about vaccination among people, and an increase in spending capacity among consumers.
The most commonly used mammalian cell cultures are Chinese Hamster Ovary (CHO) cells.
Application Insights:
Based on the application, the global recombinant protein vaccine market is segmented into human, animal and bacterial cells culture. The human application segment dominated the overall market in terms of revenue share in 2017. This can be attributed to growing incidence of diseases caused by pathogens that have evolved immunity to conventional vaccines. For instance, according to WHO estimates nearly 30 million people are currently suffering from Polio which needs a new treatment method called cell-based therapy for its eradication.
The animal application segment was estimated at USD 281.5 million in 2017 owing to high usage of these products as therapeutic tools for several chronic diseases such as arthritis and cancer which require long term care and management along with their prevention measures involving vaccination programs every few years or decades depending upon their life span respectively.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high investment in R&D, and increasing focus on developing new generation vaccines. The U.S., China, Japan, Germany are some of the leading countries investing heavily in R&D for producing these proteins based vaccines. For instance; In March 2018; GlaxoSmithKline plc announced that it had received regulatory approval for its Recombinant Protein (rPR) vaccine technology from Chinese government and this technology is expected to improve access to immunization against diseases like HCoV-1 which causes severe epidemics every year across China (Xie et al., 2018).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. The Recombinant Protein Vaccine market is expected to benefit from this trend as it offers a potential solution for preventing and managing these diseases.
- Growing demand for preventive healthcare: There is a growing demand for preventive healthcare services across the world as people are becoming more aware of the benefits associated with them. This is likely to benefit the Recombinant Protein Vaccine market as it offers an effective way to prevent various chronic diseases.
- Technological advancements: The field of recombinant protein vaccine technology continues to witness rapid advancements, thanks to ongoing research efforts by leading players in this space. This is likely to result in increased uptake of recombinant protein vaccines in years ahead, benefiting the overall market growth significantly.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Protein Vaccine Market Research Report
By Type
Bacterial Cells Culture, Mammalian Cells Culture,
By Application
Human, Animal,
By Companies
Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences, Novavax, Medicago
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Protein Vaccine Market Report Segments:
The global Recombinant Protein Vaccine market is segmented on the basis of:
Types
Bacterial Cells Culture, Mammalian Cells Culture,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Human, Animal,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- GSK
- Sanofi
- Zoties
- Elanco
- Boehringer-Ingelheim
- Indian Immunologicals
- Plumbline Life Sciences
- Novavax
- Medicago
Highlights of The Recombinant Protein Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bacterial Cells Culture
- Mammalian Cells Culture
- By Application:
- Human
- Animal
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Protein Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A recombinant protein vaccine is a vaccine that uses a protein from another organism, such as a virus or bacteria, to help the body build immunity. Recombinant proteins are made by combining pieces of the proteins from two different sources. This process makes it easier for scientists to create vaccines using these proteins and helps ensure that the vaccines are effective against all types of viruses and bacteria.
Some of the major players in the recombinant protein vaccine market are Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences, Novavax, Medicago.
The recombinant protein vaccine market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Recombinant Protein Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Recombinant Protein Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Recombinant Protein Vaccine Market - Supply Chain
4.5. Global Recombinant Protein Vaccine Market Forecast
4.5.1. Recombinant Protein Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Recombinant Protein Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Recombinant Protein Vaccine Market Absolute $ Opportunity
5. Global Recombinant Protein Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Recombinant Protein Vaccine Market Size and Volume Forecast by Type
5.3.1. Bacterial Cells Culture
5.3.2. Mammalian Cells Culture
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Recombinant Protein Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Recombinant Protein Vaccine Market Size and Volume Forecast by Application
6.3.1. Human
6.3.2. Animal
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Recombinant Protein Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Recombinant Protein Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Recombinant Protein Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Recombinant Protein Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Recombinant Protein Vaccine Demand Share Forecast, 2019-2026
9. North America Recombinant Protein Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Recombinant Protein Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Recombinant Protein Vaccine Market Size and Volume Forecast by Application
9.4.1. Human
9.4.2. Animal
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Recombinant Protein Vaccine Market Size and Volume Forecast by Type
9.7.1. Bacterial Cells Culture
9.7.2. Mammalian Cells Culture
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Recombinant Protein Vaccine Demand Share Forecast, 2019-2026
10. Latin America Recombinant Protein Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Recombinant Protein Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Recombinant Protein Vaccine Market Size and Volume Forecast by Application
10.4.1. Human
10.4.2. Animal
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Recombinant Protein Vaccine Market Size and Volume Forecast by Type
10.7.1. Bacterial Cells Culture
10.7.2. Mammalian Cells Culture
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Recombinant Protein Vaccine Demand Share Forecast, 2019-2026
11. Europe Recombinant Protein Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Recombinant Protein Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Recombinant Protein Vaccine Market Size and Volume Forecast by Application
11.4.1. Human
11.4.2. Animal
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Recombinant Protein Vaccine Market Size and Volume Forecast by Type
11.7.1. Bacterial Cells Culture
11.7.2. Mammalian Cells Culture
11.8. Basis Point Share (BPS) Analysis by Type
11.9. -o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Recombinant Protein Vaccine Demand Share, 2019-2026
12. Asia Pacific Recombinant Protein Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Recombinant Protein Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Recombinant Protein Vaccine Market Size and Volume Forecast by Application
12.4.1. Human
12.4.2. Animal
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Recombinant Protein Vaccine Market Size and Volume Forecast by Type
12.7.1. Bacterial Cells Culture
12.7.2. Mammalian Cells Culture
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Recombinant Protein Vaccine Demand Share, 2019-2026
13. Middle East & Africa Recombinant Protein Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Recombinant Protein Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Recombinant Protein Vaccine Market Size and Volume Forecast by Application
13.4.1. Human
13.4.2. Animal
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Recombinant Protein Vaccine Market Size and Volume Forecast by Type
13.7.1. Bacterial Cells Culture
13.7.2. Mammalian Cells Culture
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Recombinant Protein Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Recombinant Protein Vaccine Market: Market Share Analysis
14.2. Recombinant Protein Vaccine Distributors and Customers
14.3. Recombinant Protein Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Zoties
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Elanco
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer-Ingelheim
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Indian Immunologicals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Plumbline Life Sciences
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novavax
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Medicago
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
